Health Care Weekly: Whistleblower Suit Accuses Corcept of Off-Label Marketing; CMS Finalizes Long-Awaited Rule on NSA Dispute Process; Democrats Seek Congressional Disapproval of WISeR; FDA Publishes More Draft Guidance on Reducing Animal Testing; Optum Close to Settling FTC Insulin Case; MultiPlan, Insurers Face Price-Fixing Lawsuit in AZ; FDA 483s

Recently-unsealed whistleblower lawsuit accuses Corcept of off-label marketing. Originally filed in February 2017 on behalf of the United States of America, almost 30 states, and unnamed insurance policyholders, the just-unsealed lawsuit alleges that Corcept (CORT) engaged in off- label marketing for its flagship drug Korlym (mifepristone), leading states and the federal government to pay more […]